G3215

G3215 is a unimolecular co-agonist of the glucagon-like peptide 1 receptor (GLP-1R) and the glucagon receptor (GCGR), developed as a potential treatment for obesity and metabolic diseases. It is chemically similar to oxyntomodulin (OXM), a naturally occurring gut hormone. In phase 1 clinical trials, continuous subcutaneous infusion of G3215 in overweight or obese adults—with or without type 2 diabetes—was found to be safe and well tolerated, with mild gastrointestinal side effects that could be managed by adjusting the infusion rate. The drug demonstrated significant weight loss over a short period compared to placebo, along with reduced food intake and improved lipid profiles. Its mechanism involves dual activation of GLP-1R and GCGR, which may offer advantages in weight loss efficacy over single agonists[1][2][4][5]. Developed by Imperial College of Science Technology and Medicine, with support from Labcorp Drug Development.

Other names

Gut Hormone Analogue - Imperial College of Science